American Journal of Clinical Medicine Research
ISSN (Print): 2328-4005 ISSN (Online): 2328-403X Website: http://www.sciepub.com/journal/ajcmr Editor-in-chief: Dario Galante
Open Access
Journal Browser
Go
American Journal of Clinical Medicine Research. 2013, 1(4), 54-60
DOI: 10.12691/ajcmr-1-4-3
Open AccessArticle

Predictors of Early Virological Response of Viral Hepatitis C to Combination Therapy with Pegylated Interferon Plus Ribavirin

Ahmed Faisal1, , Ashraf Anas Zytoon2, Abdel-Naser Gad Allah3 and Alaa Dawood3

1Infectious and Endemic Diseases Unit, Internal Medicine Department, Suez Canal University, Egypt

2Radiology Department, Faculty of Medicine, Menoufiya University, Egypt

3Internal Medicine Department, Menoufiya University, Egypt

Pub. Date: September 15, 2013

Cite this paper:
Ahmed Faisal, Ashraf Anas Zytoon, Abdel-Naser Gad Allah and Alaa Dawood. Predictors of Early Virological Response of Viral Hepatitis C to Combination Therapy with Pegylated Interferon Plus Ribavirin. American Journal of Clinical Medicine Research. 2013; 1(4):54-60. doi: 10.12691/ajcmr-1-4-3

Abstract

A combination therapy with pegylated interferon (PEG-IFN) plus ribavirin (RBV) has made it possible to achieve a sustained virological response (SVR) of 50% in refractory cases with genotype 1b and high levels of plasma HCVRNA. Several factors including virus mutation and host factors such as age, gender, fibrosis of the liver, lipid metabolism, innate immunity, and single nucleotide polymorphism (SNPs) are reported to be correlated to therapeutic effects. However, it is difficult to determine which factor is the most important predictor for an individual patient. Data mining analysis is useful for combining all these together to predict the therapeutic effects, It is important to analyze blood tests and to predict therapeutic effects prior to initiating treatment. Our aim is to determine the independent contribution of factors including age, gender, viral load, liver fibrosis, hepatitis activity index sore, and the homeostasis model assessment of insulin resistance (HOMA-IR) score in predicting response to therapy in chronic hepatitis C (CHC). Multivariate analysis of factors predicting rapid (RVR) and sustained (SVR) virological response in 280 consecutive, treatment-naive CHC patients treated with peginterferon alpha and ribavirin in a prospective multicentre study.

Keywords:
predictors of early virological viral hepatitis C combination therapy pegylated interferon

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

Figure of 1

References:

[1]  Lauer G.M, Walker B.D. Hepatitis C virus infection. N Engl J Med. 2001; 345(1):41-524.
 
[2]  Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who respond less well? Ann Intern Med 2004; 140: 370-81.
 
[3]  Khattab M, Eslam M, Sharwae MA, Shatat M, Ali A, Hamdy L. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol. 2010 Sep;105(9):1970-7.
 
[4]  Egypt Demographic and Health Survey 2011. Cairo, Egypt: Ministry of Health.
 
[5]  Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS: Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282:103-107.
 
[6]  McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339:1485-1492.
 
[7]  Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998, 352:1426-1432.
 
[8]  Reichard O, Norkrans G, Fryden A, Brachonier JH, Sonnerborg A, Weiland O: Randomized double blind, placebo controlled trial of interferon alpha 2b with and without ribavirin for chronic hepatitis C. Lancet 1998, 351:83-7.
 
[9]  Di Bisceglie et al., 2007Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK. 2007;Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat, 14:721-9.
 
[10]  Sim KH, Wojccik JP, Margulies M, Wade J, Heathcote J: Human leukocyte antigen class II alleles may affect response of chronic hepatitis C to interferon therapy. J Viral Hepat 1998, 5:249-253.
 
[11]  Davis GL, Lau JY: Factorespredictive of beneficial response to therapy of hepatitis C. Hepatology 1997, 26(3 Suppl 1):122S-127S.
 
[12]  Camps J, Crisostomo S, Garcia-Granero M, Riezu-Boj JI, Civeira MP, Prieto J: Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pre-treatment variable. Gut 1993, 34:1714-1717.
 
[13]  Hayashi J, Kishihara Y, Ueno K, Yamaji K, Kawakami Y, Furusyo N, Sawayama Y: Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Arch Intern Med 1998, 158:177-181.
 
[14]  Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht KJ: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001, 358:958-965.
 
[15]  Poynard T, Marcellin P, Lee S, Niederau C, Minuk GS, Ideo G, Bain V: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998, 352:1426-1432.
 
[16]  Wazir MS, Majid AS, Solangi GA, Zuberi BF: Role of interferon and interferon plus ribavirin in the management of chronic hepatitis C. J CollPhysSurgeo, Pak 2002, 12:609-612.
 
[17]  Shafi MS, Ahmad SI, Rehana M, et al.: Daily interferon versus interferon TIW in combination with ribavirin for treatment of chronic hepatitis C. JRMC 1999, 31:20-2. hepatitis C. Aliment PharmacolTher 2010; 31: 1251-67.
 
[18]  Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who respond less well? Ann Intern Med 2004;140: 370-381.
 
[19]  Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-44.
 
[20]  Durante-Mangoni E, Zampino R, Portella G, et al. Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment. ClinInfect Dis 2009; 10: 43-9.
 
[21]  Yu ML, Dai CY, Huang JF, et al. Rapid virologic response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47: 1884-93.
 
[22]  Poordad FF. Review article: the role of rapid virological response in determining treatment duration for chronic.
 
[23]  boback D.The next era of HCV antiviral therapy. Current Infections rep.2010:12(2):79-80.1-Leiveven J: Pegasys/RBV Improves Fibrosis in Responders, relapsers & Nonresponders with Advanced Fibrosis. In 55th Annual Meeting of the American Association for the Study of Liver Disease: 2004 October 29–November 2. Boston, MA, USA;
 
[24]  Pawlotsky JM. Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Res, 2003; 59: 1-11.
 
[25]  Manns M, McHutchison J and Gordon S. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 2001; 358:958-65.
 
[26]  Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G and Gonçales FL Jr. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med, 2002; 347(13):975-82.
 
[27]  Zeuzem S, Buti M and Ferenci P. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol, 2006; 44:97-103.
 
[28]  Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boye N, Ripault MP, Paradis V, Vidaud M, Valla D, Marcellin P. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008, 134:416-423.
 
[29]  Fattovich, L. Covolo, S. Bibert, G. Askarieh, M. Lagging, S. Santantonio, and G. Raimondo. IL28B Polymorphisms, IP-10 and Viral Load Predict Virological Response to Therapy in Chronic Hepatitis C. Alimentary Pharmacology & Therapeutics 2011, 33(10):1062-1072.
 
[30]  30-Berg T, Weich V and Teuber G. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology 2009, 50:369-77.
 
[31]  Abdoul H, Mallet V, Pol S, Fontanet A. Serum Alpha-Fetoprotein Predicts Treatment Outcome in Chronic Hepatitis C Patients Regardless of HCV Genotype. PLoS ONE 2008; 3(6): e2391.
 
[32]  Kamal S M, Graham C S, He Q, Bianchi L, Tawil A A, Rasenack J W. Kinetics of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses in HCV and Schistosomamansonico infection: relation to pro-gression of liver fibrosis. J Infect Dis, 2004; 189:1140-1150.
 
[33]  Kamal S M, Madwar M A, Peters T, Fawzy R, Rasenack J. Interferon therapy in patients with chronic hepatitis C and schistosomiasis. J Hepatol 2000, 32:172-174.
 
[34]  Pérez Roldán F, De Diego A, Casado M, Matilla A, Bañares R, García-Durán F, Salcedo M, Cos E, Clemente G. Treatment with interferon alfa-2b in patients with chronic hepatitis caused by hepatitis C virus: predictive factors for the response, relapse and early development to cirrhosis after treatment. Rev EspEnferm Dig 1996, 88(9):609-15.
 
[35]  35-Pockros P J, Hamzeh F M, Martin P, Lentz E, Zhou X, Govindarajan S. Histologic Outcomes in Hepatitis C Infected Patients with Varying Degrees of Virologic Response to Interferon-Based Treatments. Hepatology 2010; 52(4):1193-1200.
 
[36]  Hosogaya S, Ozaki Y, Enomoto N, Akahane Y. ;Analysis of prognostic factors in therapeutic responses to interferon in patients with chronic hepatitis C. Transl Res, 2006 148(2):79-86.
 
[37]  Madwar M, Bianchi L, Tawil A E, Fawzy R, Peters T. Clinical, virological and histopathological features: long-term follow-up in patients with chronic hepatitis C co-infected with S. mansoni. Liver 2000, 20:281-289.
 
[38]  Balart L, Lee S S, Everson GT, Reindollar R W, Shiffman M L, Minuk G Y. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis. Aliment Pharmacol Ther 2008, 27:542-551.
 
[39]  Everson G T, Jensen D M, Craig J R, van Leeuwen D J, Bain V G, Ehrinpreis M N. Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics. HEPATOLOGY 1999, 30:271-276.
 
[40]  Shiffman M L, Hofmann C M, Thompson E B, Gonzalez F, Contos M J, Koshy A and Luketic A V. Relationship Between Biochemical, Virological, and Histological Response During Interferon Treatment of Chronic Hepatitis C. Hepatology, 1997; 26:780-785.
 
[41]  Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, Lefkowitch J H, Ludwig J, Okuda K. The long-term pathological evolution of chronic hepatitis C. HEPATOLOGY 1996;23: 1334-1340.
 
[42]  Yee LJ, Im K, Borg B, Yang H, Liang TJ. Interleukin-6 haplotypes and the response to therapy of chronic hepatitis C virus infection. Genes Immun 2009; 10:365-372.
 
[43]  Gao B. Cytokines, STATs and liver disease. Cell MolImmunol. 2005;2(2):92-100.
 
[44]  Banner BF, Barton AL, Cable EE, Smith L and Bonkovsky HL.A detailed analysis of the Knodell score and other histologic parameters as predictors of response to interferon therapy in chronic hepatitis C. Mod Pathol, 1995; 8: 232-238.
 
[45]  Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998, 352:1426-1432.
 
[46]  Romero-Gómez M, Salmerón J, Diago M, Grande L and Vázquez L. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005,128: 636-641.
 
[47]  Petta S, Cammà C and Di Marco V. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. AntivirTher 2009, 14: 631-9.
 
[48]  Bortoletto G, Scribano L and Realdon S. Hyperinsulinaemia reduces the virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance. J Viral Hepat 2010; 17: 475-80.
 
[49]  Alaei M and Negro F. Hepatitis C virus and glucose and lipid metabolism. Diabetes Metab 2008, 34: 692-700.
 
[50]  Persico M, Capasso M, Persico E, Svelto M, Russo R, Tiribelli C and Iolascon A; Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy. Hepatology 2007, 46: 1009-1015.